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Abstract
Background: Immune responses directed towards surface polysaccharides conjugated to proteins are effective in
preventing colonization and infection of bacterial pathogens. Presently, the production of these conjugate vaccines
requires intricate synthetic chemistry for obtaining, activating, and attaching the polysaccharides to protein carriers.
Glycoproteins generated by engineering bacterial glycosylation machineries have been proposed to be a viable
alternative to traditional conjugation methods.
Results: In this work we expressed the C. jejuni oligosaccharyltansferase (OTase) PglB, responsible for N-linked
protein glycosylation together with a suitable acceptor protein (AcrA) in Yersinia enterocolitica O9 cells. MS analysis
of the acceptor protein demonstrated the transfer of a polymer of N-formylperosamine to AcrA in vivo. Because Y.
enterocolitica O9 and Brucella abortus share an identical O polysaccharide structure, we explored the application of
the resulting glycoprotein in vaccinology and diagnostics of brucellosis, one of the most common zoonotic
diseases with over half a million new cases annually. Injection of the glycoprotein into mice generated an IgG
response that recognized the O antigen of Brucella, although this response was not protective against a challenge
with a virulent B. abortus strain. The recombinant glycoprotein coated onto magnetic beads was efficient in
differentiating between naïve and infected bovine sera.
Conclusion: Bacterial engineered glycoproteins show promising applications for the development on an array of
diagnostics and immunoprotective opportunities in the future.
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Background
Brucella sp., the causative agents of brucellosis, are
Gram-negative, facultative intracellular a-proteobacteria
[1-3]. Three Brucella species, B. abortus, B. melitensis,
and B. suis are the common species that cause human
brucellosis. They can also infect domestic livestock,
causing miscarriages and sterility leading to significant
economic loss [4,5]. Brucellosis is the most common
bacterial zoonosis with over half a million new cases
annually and high levels of abortions in cattle in devel-
oping countries [6,7]. In addition, Brucella sp. are con-
sidered highly effective biological weapons [1]. B.
abortus is the causative agent for brucellosis in cattle
and the second most common cause of human infec-
tions [8]. The current commercially available vaccines
against B. abortus are attenuated strains, which are
effective in livestock, but retain virulence to humans [9].
Due to this and other disadvantages, such as the impos-
sibility to discriminate between infected and vaccinated
animals during immune-screening procedures, new vac-
cines against brucellosis are required. Among several
promising vaccine candidates is a live attenuated strain
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lacking the phosphoglucomutase gene (Δpgm), which is
unable to assemble the O polysaccharide [10].
Immune responses directed towards surface polysac-
charides are effective in preventing colonization and
infection against several bacterial pathogens [11]. How-
ever, to generate long-term protection in children, the
polysaccharides must be covalently attached to an
appropriate protein carrier [11,12]. The efficacy of con-
jugating bacterial polysaccharides to proteins is best
exemplified by the Haemophilus influenzae type b con-
jugate vaccine, which has virtually eradicated the infec-
tions caused by this organism in most parts of the
world [11]. Indeed, glycoconjugate vaccines have also
been used for the prevention and treatment of a diverse
array of bacterial, viral, protozoan, parasitic, and cancer-
ous diseases [11]. Presently, the production of these
conjugate vaccines requires intricate synthetic chemistry
for obtaining, activating, and attaching the polysacchar-
ides to protein carriers [11]. The polysaccharides are
either obtained from the target pathogen, or by labor-
ious synthesis. Extraction of the polysaccharides from
pathogenic organisms usually requires large cultures,
which constitutes a major health hazard [13]. Further-
more, when purifying O antigens, chemical removal of
the endotoxin is required to prevent fever [11]. In most
cases, bacterial polysaccharides are too complex to be
synthesized efficiently by chemical methods, which
make this process economically unfavorable [13]. In the
final stage of conjugation, chemical attachment of the
carbohydrate to the protein often results in large and
heterogeneous conjugates. In addition, a considerable
amount of toxic waste is generated during the conjuga-
tion process [13]. For these reasons, production of con-
jugate vaccines using conventional procedures is
complex and the costs are prohibitive for global vaccina-
tion programs.
The O antigen of B. abortus and B. suis is a homopo-
lymer of N-formylperosamine [14,15]. Only a few stu-
dies evaluating the suitability of conjugate vaccines
against Brucella have been published. A conjugate vac-
cine obtained by covalently coupling the O-polysacchar-
ide obtained from B. melitensis to bovine serum
albumin (BSA) induced antibodies and was protective in
mice [16]. Nevertheless, because Brucella sp. requires
class III biosafety facilities, production of glycoconju-
gates containing Brucella glycans in its native host is
challenging and possibly unsafe. It has recently been
established that conjugates containing polysaccharide
from pathogenic bacteria can be produced in E. coli by
exploitation of bacterial glycosylation systems. Bacterial
oligosaccharyltransferases (OTases) are enzymes capable
of transferring glycan chains, including polysaccharides,
from lipid carriers to proteins, in a process called en
bloc protein glycosylation [17]. OTases involved in both,
N- and O-glycosylation have been characterized in bac-
teria [17,18]. The most thoroughly studied bacterial gly-
cosylation system is the N-glycosylation machinery of
Campylobacter jejuni [17,19-21]. N-glycosylation is
initiated by a specialized glycosyltransferase that attaches
a nucleotide-activated monosaccharide-1P to an undeca-
prenolphosphate (Und-P) lipid carrier on the inner face
of the inner membrane. A series of glycosyltransferases
subsequently attach additional monosaccharides to the
first sugar residue on Und-PP. When the carbohydrate
structure is completed, the Und-PP linked glycan is
flipped to the periplasmic face, where the N-OTase PglB
transfers the carbohydrate to protein acceptors with a
consensus sequence of D/E-Y-N-X-S/T (Y, X ≠ P)
[22,23]. Previous work has demonstrated that C. jejuni
PglB can transfer an array of glycans, including O-anti-
gens, from the lipid donors to carrier proteins [21]. Due
to their versatility, bacterial glycosylation systems can be
seen as toolboxes for engineering novel glycoconjugates.
Conjugates produced by this method may constitute a
new generation of vaccines, circumventing most of the
disadvantages of the conventional chemical methods,
significantly reducing costs, and improving the reprodu-
cibility of the product obtained. In this work, we
exploited the C. jejuni N-glycosylation machinery to
engineer N-linked glycoproteins and tested their possible
applications in vaccinology. We also demonstrated that
these glycoproteins have promising applications for the
diagnosis of brucellosis.
Results
Cross reactivity between Brucella and Y. enterocolitica O:9
The B. abortus and B. suis O antigens were previously
characterized by genomic analysis, NMR, and serological
assays and appear to be identical to that of Yersinia
enterocolitica O:9 (Ye O:9) [15,24,25]. Ye O:9 is a Class
II biosafety hazard organism and is easily manipulated
and cultured, making it a suitable host for the produc-
tion of the glycoconjugate protein with the N-formylper-
osamine homopolymer, which we hypothesize could
cross-protect against brucellosis [26]. In some Y. entero-
colitica strains, an additional “outer core” (OC) consist-
ing of a shorter glycan chain is assembled onto the
Und-PP carrier and subsequently ligated to lipid A. To
confirm cross reactivity of the Ye O:9 (Table 1) and the
B. abortus O antigens, LPS of both species were ana-
lyzed by SDS-PAGE and immunoblot (Figure 1). Our
analysis included the wild-type Ye O:9 strain, plus three
derivatives lacking the OC, the O antigen, or both gly-
can structures. LPS samples from of the Ye O:9 strains
exhibited a different electrophoretic pattern according
to the mutation carried by each strain. The double
mutant strain only displayed a band corresponding to
lipid A core (lane 1). The O antigen deficient strain
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exhibited a unique band that migrated slower than the
lipid A core, as expected for the presence of the low
molecular weight OC structure attached to the lipid A
(lane 2). The OC minus strain only produced the high
molecular weight homopolymer (lane 3), and the WT
strain produced both glycan structures (lane 4; Figure
1A). Analysis of the LPS extracts using monoclonal anti-
bodies (Figure 1B, C) demonstrated that only the high
molecular weight carbohydrate of Ye O:9 was reactive
towards the Yst9-2 (anti-Ye O:9 antigen) monoclonal
antibody (mAb; Figure 1B, lanes 3 and 4). The Yst9-2
mAb antibody also recognized the O antigen of B abor-
tus, B. melitensis and B. suis, confirming the cross reac-
tivity of the LPS between the species (Figure 1B, Lanes
5-7). The M84 mAb directed against B. abortus O anti-
gen also reacted with the Ye O:9 polysaccharide (Figure
1C, lanes 3 and 4). Interestingly, B. melitensis LPS did
not react towards the M84 antibody (Figure 1C, lane 6).
This result was not totally unexpected because although
the B. abortus and B. melitensis polysaccharides have a
similar composition, there are structural differences
between their O antigens [27]. These results confirmed
that the O antigens of Ye 0:9 and B. abortus have a
similar structure, and suggested that a conjugate carry-
ing the Ye O:9 antigen could mount an immune
response that may be cross-protective against B. abortus.
Purification of glycosylated AcrA from Y. enterocolitica
O:9 strains
In earlier work, N-glycosylated AcrA was synthesized in
E. coli by co-expression of C. jejuni PglB and AcrA with
an appropriate carbohydrate structure [22]. In order to
determine if we could transfer the Ye 0:9 carbohydrate
structures to AcrA in Ye O:9, we transformed each of
the strains with pMAF10, expressing PglB under an ara-
binose-inducible promoter, and pMH5, expressing a 6-
His-tagged version of AcrA. Cultures of each trans-
formed strain were grown and induced as required, and
AcrA was purified from periplasmic extracts by affinity
chromatography and analyzed by SDS-PAGE (Figure 2).
The single band visualized by Coomassie stain (Figure
2A) suggested that AcrA was unglycosylated in the dou-
ble mutant strain (lane 1), while the two glycosylation
sites of AcrA were modified with OC in the O antigen
mutant strain producing an additional two bands (lane
2). The large molecular weight O antigen was trans-
ferred to AcrA in the OC mutant strain (lane 3, and 3*),
and both glycan structures were bound to AcrA in the
Ye O:9 WT (lane 4). Additionally, the purified AcrA
samples were analyzed by immunoblot using a-AcrA
antibodies (Figure 2B). The different pattern observed in
each sample confirmed that different glycans were
attached in each strain. Interestingly, unglycosylated
AcrA appeared as a double band (lane 1). The OC
mutant strain displayed a pattern compatible with a
poorly glycosylated form of AcrA with the O antigen
(Figure 2A and 2B, lanes 3 and 3*). These conclusions
were further supported by a immunoblot of the same
samples using the a-Yersinia O:9 (Yst9-2) and the a-
Brucella O antigen (M84) monoclonal antibodies (Figure
2C and 2D, respectively). These results indicated the C.
jejuni glycosylation system was efficiently reconstituted
in Y. enterocolitica O:9. Although the OC- mutant
would be the ideal strain for the generation of the con-
jugate carrying the O:9 antigen, the unexpectedly low
AcrA glycosylation levels in this strain prevented its uti-
lization for the production of the conjugate. For this
reason, the conjugate containing the Ye O:9 antigen was
purified from the wild-type strain.
Identification of the carbohydrates attached to AcrA by
mass spectrometry
In order to fully characterize the carbohydrates attached
to AcrA, mass spectrometry techniques were employed.
AcrA was purified from Ye O9 strains, separated by
SDS-PAGE, the bands of interest were excised and in-
gel digested with trypsin, and the resulting peptides ana-
lyzed by ESI-Q-TOF MS and MS/MS. Examination of
the higher molecular weight smear from the Ye O:9 WT
glycosylated AcrA by MS revealed a peak at 1954.71+
M/Z, and subsequent analysis of this peak by MS/MS
identified the known glycopeptide DFNR modified with
a carbohydrate moiety (Figure 3A). We identified a Hex-
NAc-Hex disaccharide followed by a 173 M/Z repeat,
which corresponds to the N-formylperosamine homopo-
lymer, attached to the tetrapeptide DFNR, which
Table 1 Strains and Plasmids used in this study
Strain/Plasmid Description Source
pMAF10 HA-tagged PglBCj cloned in pMLBAD, Tmp
R (11)
pMH5 Soluble periplasmic hexa-His-tagged AcrA under control of Tet promoter, in pACYC, CmR (11)
YeO9-c-OC (OC-) Δ(wzx-wbcL)::KmGB; OC negative; derivative of Ruokola/71-c (35)
YeO9-OC-R (OC-/HP-) Phage ∅R1-37-resistant spontaneous OC-negative derivative of YeO9-R1 (35)
YeO9-R1 (HP-) Δper::KmGB; rough (O-antigen negative); Kmr derivative of Ruokola/71 (32,35)
Ruokola/71-c (WT) Spontaneous virulence plasmid-cured derivative of Ruokola/71 (32)
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represents one of the known glycosylation sites of AcrA
(Figure 3A). MS analysis of the glycoprotein produced
by O antigen deficient strain revealed a peak of 1284.63+
M/Z. MS/MS analysis of this peak identified the second
known glycosylated site of AcrA (AVFDNNNSTLLPGA-
FATITSEGFIQK) modified with the hexasaccharide
HexNAc-HexNAc-Hex-Hex-HexNAc-Hex (Figure 3B).
This hexasaccharide is known as the outer core and is
also present in Y. enterocolitica O:3. Contrary to pre-
viously published work, the outer core of Ye O:9 is
therefore not structurally homologous to that of Y.
enterocolitica O:3, despite genetic homology [28,29].
Figure 1 Cross reactivity between Y. enterocolitica O:9 and
Brucella spp. LPS samples. (0.2 OD/sample loaded) on 15% SDS-
PAGE: A) LPS silver stain analysis of samples of Y. enterocolitica 1)
OC-/HP-, 2)HP-, 3) OC-, 4) WT; Brucella 5) B. abortus, 6) B. melintensis,
and 7) B. suis. B) Immunoblot against the same samples with
monoclonal a-Yersinia (Yst 9-2). C) Immunoblot of the same
samples using monoclonal a-Brucella (M84). Cross reactivity
Figure 2 Proteins carrying Y. enterocolitica O:9 O-antigens are
immunoreactive against a-Yersinia and a-Brucella monoclonal
antibodies. Each strain was transformed with pMAF10 (pglBCj) and
pMH5 (acrA), and glycosylated AcrA was purified from 1 L of culture
using Ni2+ affinity chromatography. After purification, samples were
loaded onto a 10% SDS-PAGE gel and analyzed by: A) Coomassie
brilliant blue (5 μg/sample), immunoblot (2 μg/sample) using B) a-
AcrA, C) a-Ye O:9 (Yst9-2) mAb, or D) a-Brucella O antigen M84
mAb. Samples were purified from the following strains: 1) OC-/HP-,
2) HP-, 3) OC-, 4) WT, and 3*) 10 × loaded volume of 3 (OC-).
between the two different genus’ LPS is observed by both
monoclonal antibodies reacting against the higher molecular
weight homopolymeric N-formylperosamine polysaccharide.
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Immune Response in BALB/c Mice vaccinated with
O9-glycosylated AcrA
To evaluate the potential use of the glycoprotein as con-
jugate vaccine, the purified AcrA containing the Ye O:9
antigen was injected intraperitoneally into mice to mea-
sure the immune response as well as test subsequent
protection against a challenge with B. abortus. The con-
centration of purified glycosylated AcrA was quantified
as 1.77 mg/mL for protein and 0.71 mg/mL for carbohy-
drate, giving a protein: carbohydrate ratio of 2.48. Three
separate groups of mice were injected, one with ungly-
cosylated AcrA and two with different amounts (1.5 μg
Figure 3 ESI-Q-TOF MS and MS/MS analysis of of Y. enterocolitica O:9 glycobioconjugates. A) MS of high molecular weight glycosylated
AcrA purified from Ye O:9 WT revealed the peak 1954.7 M/Z. MS/MS of this peak showed a disaccharide of HexNAc-Hex linking a characteristic
173 M/Z pattern corresponding to the N-formylperosamine subunit to the known glycopeptide DFNR. B) MS of high molecular weight
glycosylated AcrA purified from Ye O:9 O antigen mutant revealed the peak 1284.63+ M/Z. MS/MS of this peak shows the second known
glycosylated site of AcrA (AVFDNNNSTLLPGAFATITSEGFIQK) modified with the hexasaccharide HexNAc-HexNAc-Hex-Hex-HexNAc-Hex.
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and 3 μg of carbohydrate per mouse) of glycosylated
AcrA, respectively. After a second injection of glycopro-
tein, sera obtained from the control (Figure 4A, C, and
4E) and 3 μg group (Figure 4B, D, and 4F) were ana-
lyzed for IgG immune response by immunoblot. As
expected, both sets of sera reacted strongly against
AcrA (Figure 4A, b). However, when the sera were
assayed against the purified Y. enterocolitica LPS, only
the groups injected with glycosylated AcrA were reactive
against purified LPS samples from Y. enterocolitica O:9
OC mutant and WT strains, indicating that IgG antibo-
dies against the N-formylperosamine homopolymer
were generated (Figure 4C, D). No reactivity was
observed for the control sera towards the Brucella LPS,
whereas the sera from the mice injected with glycosy-
lated AcrA showed a strong immunoreactivity towards
the B. abortus and B. suis LPS (Figure 4E, F). A very
weak response was observed against the B. melintensis
LPS.
The generation of antibodies against the Ye O:9 antigen
was further analyzed by ELISA. Each well was coated
with 12.5 μg of Ye O:9 LPS (Figure 5). Of the three
groups of mice, only the sera from mice belonging to the
two groups inoculated with glycosylated AcrA showed an
IgG response directed towards the polysaccharide. How-
ever, a high level of variation in the absorbance values
was observed, with some animals showing no significant
response. Interestingly, the group of mice inoculated with
the lower amount of glycoprotein (1.5 μg) exhibited a
higher average OD405 nm than the group inoculated with
3 μg. Nevertheless, the immune response was insufficient
or inefficient in protecting the mice against a challenge
with B. abortus, as no statistical difference was observed
in bacterial load in the spleen of infected mice irrespec-
tive of whether they were injected with glycosylated or
unglycosylated AcrA (data not shown).
Figure 4 Sera of BALB/c mice immunized with bioconjugate
shows a directed IgG immune response against N-
formylperosamine of Y. enterocolitica O:9 and Brucella spp. A)
Control sera and B) Immune sera raised by injecting purified
glycoproteins containing 3 μg glycan: 1) Unglycosylated AcrA, 2)
HP-, 3) OC-, 4) WT. Both sets of sera react with each glycoprotein
due to the high immunostimulatory characteristic of AcrA. C)
Control sera and D); immune serum (IgG response) blotted against
Y. enterocolitica 0:9 LPS from different strains from Figure 1. 5) OC-/
HP-, 6) HP-, 7) OC-, 8) WT. Only the test serum was reactive against
the higher molecular weight portion corresponding to the
homopolymer of N-formylperosamine. E) Control sera and F)
immune serum blotted against Brucella spp. LPSs: 9) B. abortus, 10)
B. melitensis, and 11) B. suis. Only the immune sera are reactive
against the Brucella LPS. Interestingly, although each LPS is
comprised of N-formylperosamine, different linkages are present
which may cause the difference in reactivity of the sera.
Figure 5 BALB/c mice elicit an IgG immune response against Y.
enterocolitica LPS, but is not protective against B. abortus
infection. A) ELISA response of the sera obtained from the third
bleed (1/200 dilution) of the different mouse groups against Y.
enterocolitica O:9 LPS. Microtiter plates were coated with 12.5 μg of
Y. enterocolitica O:9 LPS. Each datum point represents the average
of three replicate wells. Response was read after 1 h @ 37°C at
OD405 nm. The bar in each set of data corresponds to the average of
each group.
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Glycoconjugates as novel antigens for the diagnosis of
brucellosis
Because vaccination with the glycosylated AcrA induced
the production of a specific IgG immune response
against the O-antigen, we asked if this glycoconjugate
could be used as an antigen for the diagnosis of the infec-
tion in cows. To test this, we immobilized AcrA (control)
or AcrA-O:9 on paramagnetic microbeads (see Materials
and Methods) and tested the reactivity towards sera from
non-infected animals, as well as from cows vaccinated
with the B. abortus Δpgm or infected with B. abortus
2308 strain. These animals are part of an efficacy trial to
test the protective capacity of the Δpgm strain [10,30]
(manuscript in preparation). As mentioned earlier, Δpgm
is a rough strain that does not induce the production of
anti-O-antigen specific immunoglobulin titers in mice.
As can be observed in Figure 6A, the assay clearly
differentiates non-infected from infected animals and
does not react with sera from animals vaccinated with a
strain that lacks a complete LPS. Additionally, it is shown
that none of these sera reacted against the non-glycosy-
lated form of AcrA in a immunoblot indicating that the
IgG response detected is directed specifically towards the
carbohydrate moiety of the antigen (Figure 6B). Taken
together, these results strongly suggest that this novel
antigen could be used for the development of new diag-
nostic tools for brucellosis.
Discussion
Because the Y. enterocolitica O:9 and B. abortus LPSs
share the same structure, we hypothesized that a glyco-
protein carrying the Ye O:9 glycan would be able to
generate antibodies recognizing B. abortus O polysac-
charide, with the overall goal of eliciting a protective
Figure 6 Y. enterocolitica O:9 bioconjugate as a promising antigen for the diagnosis of bovine brucellosis. A) Magnetic bead-based
immunoassay for detection of antibodies against Brucella abortus O-antigen. Magnetic beads coated with the AcrA-OAg glycoconjugate were
incubated with the indicated bovine serum samples (dilution 1/200). Bound antibodies were detected using a Cy5-conjugated goat anti-bovine
IgG. The bar graph data represents the means and standard deviation for two separate determinations. Control: magnetic beads incubated with
PBS-Tween 0.1%. B) Immunoblot of the same bovine serum samples.
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immune response against infection by this organism. We
also explored if such a glycoprotein could be used for
the diagnosis of brucellosis. We confirmed, using immu-
noblot, that mAb raised against Yersinia O:9 and B.
abortus O antigens can cross-react with both structures.
A glycoprotein consisting of the Y. enterocolitica O:9
antigen attached to the carrier protein AcrA was
obtained in vivo by expression of the N-linked protein
glycosylation OTase PglB of C. jejuni in Y. enterocolitica
strains. The glycoprotein was purified from Ye O:9 cells
and characterized by MS techniques. We confirmed the
attachment of a polymer of N-formylperosamine to
AcrA, which was reactive towards two mAbs directed
against Ye O:9 and B. abortus O antigens, respectively.
However, we also identified a previously unreported dis-
accharide with the formula HexNAc-Hex acting as a lin-
ker between the protein and the Ye O:9 homopolymer.
A similar linker has been described in many homopoly-
meric O antigens in different bacterial species [31] and
also in other polysaccharides such as the arabinogalac-
tan of M. tuberculosis and the teichoic acids in Gram-
positive bacteria ([32]. This indicates that disaccharides
acting as linkers are a common feature in the synthesis
of bacterial polysaccharides via the polymerase (wzy)
independent pathway. Additionally, MS/MS analysis
demonstrated the attachment of shorter glycan to AcrA
in the wild type strain, with a structure of HexNAc-
HexNAc-Hex-Hex-HexNAc-Hex. This hexasaccharide is
known as the outer core and is also present in Y. entero-
colitica O:3. Based on genetic similarities within the O:9
and the O:3 strains, it was hypothesized that the struc-
tures in both strains would be identical. However, our
results demonstrate that a different structure is gener-
ated in the O:9 strain [29,33].
Injection of AcrA-O9 in mice was able to elicit an IgG
immune response against the O:9 polysaccharide. Sera
of inoculated mice reacted with Ye O:9 LPS, and B.
abortus and B. suis O antigens. However, the reaction
towards B. melitensis O polysaccharide was practically
undetectable. B. abortus has both an A (a-1,2-linked
homopolymer of N-formyperosamine) and an M (penta-
saccharide with four a-1,2 and one a-1,3-linked poly-
mers of the same sugar) epitope [14]. Y. enterocolitica
O:9 antigen is comprised solely of a1,2-linked N-formyl-
perosamine, B. abortus has ~98% A epitope, B. suis has
a unique 1:7 ratio of a1,3- a1,2 linked polymer, whereas
B. melitensis has only the M antigen of the pentasac-
charide repeat [14]. These structural details help to
explain why the M84 mAb against B. abortus does not
recognize B. melitensis LPS, as this mAb is likely direc-
ted to an epitope absent in B. melitensis. However, the
three Brucella strains reacted against the mAb a-Yersi-
nia antibody, reflecting common epitopes that exist in
the four structures (Figure 1B). We therefore expected
that these common epitopes present in the AcrA-O9
glycoprotein would elicit antibodies that would also
cross react with B. melitensis LPS, but the sera of the
mice injected with AcrA-O9 failed to recognize B. meli-
tensis LPS. This indicates that the common epitopes in
all the structures are not the immunodominant ones.
Interestingly, although AcrA was glycosylated with both
the Ye O:9 and the OC glycan structures, only the O:9
antigen was detected by the mice sera, suggesting that
the outer core is not immunogenic (Figure 4D).
A previous report suggested that a conjugate contain-
ing BSA and the O polysaccharide of B. melitensis was
protective in mice [16]. In preliminary experiments we
found that passive immunization with the Yst9 mAb
was protective against B. abortus challenge (data not
shown). These results prompted us to test the efficacy
of our recombinant glycoconjugate against B. abortus
challenge. An elevated dispersion in the titers of the
vaccinated mice was obtained. However, no correlation
between antibody titers and bacterial load in the spleen
was found, resulting in the absence of difference in bac-
terial colonization of the three groups. Lack of protec-
tion could possibly be explained by the fact that B.
abortus is an intracellular pathogen and that antibodies
against this bacterium may not be able to encounter the
microorganism once the infection is established. Alter-
natively, higher antibody titers may be necessary to elicit
a protective immune response. The antibody titers were
higher in the animals vaccinated with the lowest amount
of glycoconjugate. It is possible that lower amounts of
antigen may have to be injected to obtain protective
antibody titers.
Our AcrA-O9 conjugate showed promising applica-
tions in the diagnostics of brucellosis. Diagnostics of
brucellosis using lipopolysaccharide (LPS) as an antigen
have been previously explored [34]. LPS are large mole-
cules that also contain a core polysaccharide and a lipid
A moiety, as well as the O antigen. LPS-based assays
often suffer from false positives due to the presence of
antibodies against common core antigen and lipid A,
generated by other bacterial species. Here, we showed
that coating magnetic beads with the AcrA-O:9 glyco-
protein allows the distinction between infected and
uninfected cows. The assay will be particularly useful in
conjunction with vaccines like the RB51 or the Δpgm
strain, which do not have O antigen, as our assay will
allow the distinction between vaccinated and infected
animals. Further studies will be carried out to confirm
the suitability, i.e. sensitivity and specificity of this assay
for detection of bovine and human brucellosis.
Ten years have gone by since the demonstration that
bacterial glycosylation systems can be successfully trans-
ferred into E. coli. Since then we have learned that the
bacterial OTases have a relaxed specificity and are able
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to transfer a variety of glycans, including O antigens, to
suitable protein acceptors. The experiments presented
here demonstrate that an IgG immune response can be
mounted against the glycan moieties in bacterial glyco-
proteins. Further work will expand these efforts for the
generation of novel vaccines against other important
bacterial pathogens. Furthermore, we also expect that
the platform presented here for the detection of brucel-
losis will also be applied in the future for the design of
additional bacterial-glycoprotein based diagnostic
methods.
Conclusions
In summary, the C. jejuni N-glycosylation system can be
exploited to engineer designer glycoproteins. These gly-
coproteins can be utilized for carbohydrate characteriza-
tion, vaccinology, and diagnostics. Mice injected with
the YeO9-AcrA glycoconjugate were able to develop
immune responses towards different Brucella sp., but
protection was not achieved. When magnetic beads
were coated with the YeO9-AcrA recombinant glycopro-
tein, differentiation between naïve and B. abortus
infected bovine sera was easily discernable. These new
biologically engineered glycoconjugates may be devel-
oped for a vast array of diagnostic and immunoprotec-
tive opportunities in the future.
Materials and methods
Bacterial strains, plasmids, and growth conditions
Yersinia enterocolitica O:9 strains were grown in LB
media @ 37°C. Trimethoprim (100 μg/mL) and chlor-
amphenicol (20 μg/mL) were used for plasmid selection
as required. The strains and plasmids used in this study
are listed in Table 1.
Production and purification of glycosylated AcrA
Ye O:9 strains transformed with C. jejuni PglB
(pMAF10) and AcrA (pMH5) were grown overnight at
37°C. Cultures were reinnoculated 1/100 into fresh LB
media and grown at 37°C for 2.5 h (OD600 ~0.5) and
PglBCj expression was induced with addition of arabi-
nose to a final concentration of 0.2% (w/v). Four hrs
after induction at 37°C, PglBCj was re-induced by a sec-
ond addition of arabinose to maximize glycosylation of
AcrA. Cells were harvested by centrifugation after a 20
h induction period and periplasmic extracts were pre-
pared by lysozyme treatment as described elsewhere
[21]. Subsequently, the periplasmic fraction was equili-
brated with 1/9 vol 10 × loading buffer (0.1 M Imidi-
zole, 3 M NaCl, 0.2 M Tris-HCl pH 8.0) and subjected
to a Ni2+ affinity chromatography. The column was
equilibrated with 10 column volumes of 1 × loading buf-
fer and loaded on a HisTrap HP column (Amersham
Pharmacia Biosciences) at a flow rate of 1 mL/min. The
column was washed with 25 column volumes of wash
buffer (0.02 M Imidazole, 0.3 M NaCl, 0.02 M Tris-HCl
pH 8.0), and eluted from the column by elution buffer
(0.250 M Imidazole, 0.3 M NaCl, 0.02 M Tris-HCl pH
8.0).
LPS extraction
LPS was extracted using the hot phenol-water method
as described [35]. The LPS extract was resuspended in 2
mL of distilled H20.
Sugar quantification of glycoproteins
Protocol was adapted from the total sugar quantification
protocol [36]. Briefly, mix in a glass tube 90 μL ddH20,
10 μL of sample, and 100 μL of 5% phenol (freshly
made) in ddH20. Briskly add 1 mL of conc. H2SO4 into
the mixture and immediately vortex the solution for sev-
eral seconds. An orange color with intensity propor-
tional concentration will begin to develop immediately
and reach a maximum after 2 h @ 30°C. Read against
chemically synthesized N-formylperosamine standards @
OD500 nm.
Western immunoblot
Western immunoblot was performed based on the pro-
cedure described in [37]. Samples were separated on
10% or 15% SDS-PAGE gels and transferred to a nitro-
cellulose membrane via semi-dry membrane transfer
and analyzed with a variety of antibodies. a-AcrA anti-
body [38], Yst9-2 antibody [25], and Brucella antibodies
M84 [39] were employed as previously described.
Mass Spectrometry
The nickel column purified protein/glycoprotein was
subsequently separated by SDS-PAGE, and the bands
corresponding to the desired protein and glycoprotein
were in-gel digested with trypsin (Promega) using the
protocol of Shevchenko et al. with modification [40].
Briefly, the bands corresponding to the glycoproteins
were excised and transferred to 1.5 ml Eppendorf vials.
After destaining with 50 mM ammonium bicarbonate in
50% acetonitrile/water, the gel pieces were dehydrated
with acetonitrile and rehydrate with 10 μl of (~2 μg)
trypsin. Then the sample was left in 37°C oven for over-
night digestion after addition of 50 μl ammonium bicar-
bonate (50 mM) aqueous. The samples were extracted
using Zip-Tips (Millipore), and analyzed using a hybrid
quadrupole orthogonal acceleration time-of-flight mass
spectrometer (Waters, UK) equipped with ananoAC-
QUITY Ultra Performance liquid chromatography sys-
tem (Waters, Milford, MA). Briefly, 2 μl of the peptide
solution was injected on to a VanGuard micro precol-
umn C18 cartridge that is connected to a 75 um i.d. ×
150 um Atlantis dC18 column (Waters, Milford, MA).
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Solvent A consisted of 0.1% formic acid in water, and
solvent B consisted of 0.1% formic acid in acetonitrile.
After 1 min trap wash in the precolumn with solvent A
at flow rate of 10 μl/min, peptides were separated using
solvent gradient and electrosprayed to the mass spectro-
meter at a flow rate of 350 nl/min. The collision energy
used to perform MS/MS was varied according to the
mass and charge state of the eluting peptides. The
instrument is calibrated every 1 min with GFP and
LecErK using the LockSpray. For the data acquisition
and analysis, MassLynx (Waters MassLynx V4.1) was
used.
Mouse trials experimental design
A group of 18 BALB/c female mice were divided into 3
groups and injected intraperitoneally with 1.5 or 3 μg of
glycosylated AcrA (carbohydrate quantity) or equivalent
unglycosylated control in aluminum hydroxide per
mouse. The mice were injected with three doses of 2
weeks interval and the challenge was 1 week after the
third dose with the virulent B. abortus 2308 also via IP.
The mice were bled via tail bleed method, resulting in a
blood sample of 5-25 μL. The blood was allowed to coa-
gulate at 24°C for 4 h, after which the samples were
centrifuged for 10 min @ 13,000 rpm to isolate the
blood sera. The sample was stored at -20°C until ana-
lyzed. Injections were done according to the TiterMax®
Kontes Pellet Pestle® Homogenizer method using Titer-
Max® Gold. A second bleeding of the mice occurred 6
weeks after the initial injection, resulting in similar sera
yields. The mice were given a second injection with the
same quantities of sample. The third and final bleed
occurred 4 weeks after the second injection, and was
also stored @ -20°C until required for analysis.
ELISA analysis of Mouse Sera
ELISA analysis was done (Costar® polystyrene High
Binding plate) and optimized from (5). 100 μl of each of
Y. enterocolitica O:9 (12.5 μg/mL LPS), Brucella meli-
tensis (50 μg/mL LPS), and purified AcrA (1 μg/mL)
was determined to give the optimal colorimetric
response in 0.05 M sodium carbonate buffer (pH 9.8).
Wells were blocked using 2.5% (wt/vol) skim milk in
PBS buffer for 1.5 h. Sera from the mice were diluted 1/
200 in PBS buffer, and 100 μL was placed in each well.
Plates were washed 3 times with PBST. The 2o antibo-
dies conjugated to alkaline phosphatase (Biorad Labora-
tories) were incubated at a dilution of 1:3000 for 1 h at
room temperature. Plates were washed 5 times with
PBST, and were incubated with 100 μL p-nitrophenol-
phosphate substrate (1 mg/mL) in 0.05 mM sodium car-
bonate buffer (pH 9.8) for 1 h @ 37°C. Plates were read
at OD405 nm.
Brucella challenge against injected BALB/c mice
Groups of 6 Balb/c female mice intraperitonelly vacci-
nated with either 1.5 or 3 μg of the glycoconjugate were
challenged 4 weeks after the second dose with 5 × 104
CFUs intraperitoneally of wild type B. abortus 2308 and,
2 weeks post-infection, the bacterial load in the spleens
determined as previously described [10].
Magnetic-bead based immunoassays
Superparamagnectic COOH-modified microbeads
(Bangs’s Laboratories) were coated with the AcrA-OAg
glycoconjugate in one step using EDAC [1-ethyl-3-(3-
dimethyl-aminopropyl) carbodiimide hydrochloride] and
NHS [N-hydroxy succinimide] reactives. Functionalized
microbeads were incubated with bovine serum samples
(dilution 1/200) and bound antibodies were detected
using a Cy5-conjugated goat anti-bovine IgG (Biomeda).
Fluorescence reading was performed using a plate fluo-
rometer (DTX 880 Multimode Detector, Beckman
Coulter).
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